Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp (NASDAQ:TWST), filed a Form 4 on August 27, 2026, disclosing the sale of 41,570 shares of common stock on August 25, 2026, pursuant to a previously adopted Rule 10b5-1 trading plan.

Key Highlights

  • Total shares sold: 41,570 shares of common stock disposed of on August 25, 2026, across five separate transactions.
  • Price range: Weighted average sale prices ranged from $150.564 to $154.446 per share across the five tranches.
  • Remaining direct ownership: Following the transactions, Leproust directly beneficially owned 770,729 shares of common stock.
  • Trading plan: All sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2025.
  • Derivative holdings retained: Leproust continues to hold employee stock options covering shares at exercise prices of $8.82, $26.66, $23.33, and $67.85, with varying vesting schedules.

Leproust's August 2026 Share Sales at Twist Bioscience: Transaction Details

According to the filing, Emily M. Leproust, who serves as both Chief Executive Officer and a Director of Twist Bioscience Corp, disposed of common stock in five separate tranches on August 25, 2026. The transactions carried transaction code "S," indicating open-market sales. The filing notes that all sales were made under a Rule 10b5-1 trading plan that Leproust adopted on May 27, 2025.

The five tranches were: 12,648 shares at a weighted average price of $150.564 (range $150.00 to $150.99); 12,236 shares at $151.355 (range $151.00 to $151.97); 6,412 shares at $152.75 (range $152.33 to $153.32); 9,181 shares at $153.927 (range $153.34 to $154.33); and 1,093 shares at $154.446 (range $154.34 to $154.64). The filing states that each price listed represents the weighted average sale price per share, and that full information on shares sold at each specific price is available upon request to the SEC, the issuer, or a security holder.

Following all reported sales, the filing discloses that Leproust directly and beneficially owns 770,729 shares of common stock. The filing also lists several employee stock options that were not subject to transactions in this report, including options with exercise prices of $8.82 covering 75,439 underlying shares, $26.66 covering 133,269 shares, $23.33 covering 131,290 shares, and $67.85 covering 64,950 shares. The $67.85 options, according to the filing, are performance stock options that vested on December 19, 2022, following the reporting person having met applicable performance criteria.

What Was Disclosed

The filing reports the disposal of 41,570 shares of Twist Bioscience common stock by CEO Emily M. Leproust on August 25, 2026, under a pre-established Rule 10b5-1 plan, leaving her with direct beneficial ownership of 770,729 shares.